Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Surgery Partners Analyst Ratings and Price Targets | NASDAQ:SGRY | Benzinga
Surgery Partners Inc has a consensus price target of $38.77 based on the ratings of 14 analysts. The high is $51 issued by Barclays on August 2, 2023. The low is $28 issued by JP Morgan on December 3, 2024. The 3 most-recent analyst ratings were released by Benchmark, RBC Capital, and Macquarie on April 21, 2025, March 25, 2025, and March 11, 2025, respectively. With an average price target of $34.33 between Benchmark, RBC Capital, and Macquarie, there's an implied 49.73% upside for Surgery Partners Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
RBC Capital
Macquarie
JP Morgan
UBS
1calculated from analyst ratings
Analyst Ratings for Surgery Partners
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/21/2025 | Buy Now | 52.64% | Benchmark | Bill Sutherland73% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2025 | Buy Now | 52.64% | RBC Capital | Ben Hendrix61% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2025 | Buy Now | 43.92% | Macquarie | Tao Qiu55% | $34 → $33 | Maintains | Outperform | Get Alert |
| 12/03/2024 | Buy Now | 22.11% | JP Morgan | Lisa Gill41% | $38 → $28 | Maintains | Neutral | Get Alert |
| 11/20/2024 | Buy Now | 52.64% | RBC Capital | Ben Hendrix61% | $49 → $35 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 48.28% | Macquarie | Tao Qiu55% | $34 → $34 | Maintains | Outperform | Get Alert |
| 11/13/2024 | Buy Now | 48.28% | Macquarie | Tao Qiu55% | $35 → $34 | Maintains | Outperform | Get Alert |
| 11/04/2024 | Buy Now | 52.64% | Macquarie | Tao Qiu55% | $35 → $35 | Maintains | Outperform | Get Alert |
| 10/14/2024 | Buy Now | 65.72% | UBS | A.J. Rice71% | → $38 | Initiates | → Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Keybanc | Matthew Gillmor66% | — | Initiates | → Sector Weight | Get Alert |
| 10/04/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 08/26/2024 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/20/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2024 | Buy Now | 57% | Citigroup | Jason Cassorla56% | $38 → $36 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 113.69% | RBC Capital | Ben Hendrix61% | $49 → $49 | Reiterates | Outperform → Outperform | Get Alert |
| 07/10/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 07/09/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 07/02/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 06/28/2024 | Buy Now | 35.19% | Macquarie | Tao Qiu55% | → $31 | Initiates | → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 65.72% | Citigroup | Jason Cassorla56% | $42 → $38 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 03/06/2024 | Buy Now | 52.64% | Barclays | Andrew Mok56% | → $35 | Initiates | → Equal-Weight | Get Alert |
| 03/05/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | Buy Now | 113.69% | RBC Capital | Ben Hendrix61% | $49 → $49 | Reiterates | Outperform → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 83.17% | Citigroup | Jason Cassorla56% | $43 → $42 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 52.64% | TD Cowen | Gary Taylor58% | $39 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/12/2023 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 122.42% | Barclays | Marc Solecitto59% | $56 → $51 | Maintains | Overweight | Get Alert |
| 07/31/2023 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 118.05% | Mizuho | Ann Hynes85% | $48 → $50 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 96.25% | B of A Securities | Kevin Fischbeck72% | $42 → $45 | Upgrade | Neutral → Buy | Get Alert |
| 05/12/2023 | Buy Now | 109.33% | Mizuho | Ann Hynes85% | → $48 | Initiates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 104.97% | RBC Capital | Ben Hendrix61% | → $47 | Reiterates | → Outperform | Get Alert |
| 05/02/2023 | Buy Now | 118.05% | Benchmark | Bill Sutherland73% | → $50 | Reiterates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 104.97% | Citigroup | Jason Cassorla56% | $40 → $47 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 87.53% | Cantor Fitzgerald | Sarah James51% | → $43 | Initiates | → Overweight | Get Alert |
| 03/06/2023 | Buy Now | 104.97% | Benchmark | Bill Sutherland73% | → $47 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 74.44% | JP Morgan | Lisa Gill41% | $45 → $40 | Maintains | Neutral | Get Alert |
| 01/18/2023 | Buy Now | 144.22% | Barclays | Marc Solecitto59% | $69 → $56 | Maintains | Overweight | Get Alert |
| 12/05/2022 | Buy Now | 104.97% | Benchmark | Bill Sutherland73% | $60 → $47 | Maintains | Buy | Get Alert |
| 11/23/2022 | Buy Now | 109.33% | RBC Capital | Ben Hendrix61% | $58 → $48 | Maintains | Outperform | Get Alert |
| 11/22/2022 | Buy Now | 74.44% | SVB Leerink | Whit Mayo56% | $55 → $40 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 152.94% | RBC Capital | Ben Hendrix61% | $62 → $58 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 139.86% | SVB Leerink | Whit Mayo56% | $57 → $55 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 65.72% | Citigroup | Jason Cassorla56% | $49 → $38 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 170.39% | RBC Capital | Ben Hendrix61% | $65 → $62 | Maintains | Outperform | Get Alert |
| 06/15/2022 | Buy Now | 57% | B of A Securities | Kevin Fischbeck72% | → $36 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Surgery Partners (SGRY) stock?
The latest price target for Surgery Partners (NASDAQ:SGRY) was reported by Benchmark on April 21, 2025. The analyst firm set a price target for $35.00 expecting SGRY to rise to within 12 months (a possible 52.64% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Surgery Partners (SGRY)?
The latest analyst rating for Surgery Partners (NASDAQ:SGRY) was provided by Benchmark, and Surgery Partners reiterated their buy rating.
When was the last upgrade for Surgery Partners (SGRY)?
The last upgrade for Surgery Partners Inc happened on November 14, 2023 when TD Cowen raised their price target to $35. TD Cowen previously had a market perform for Surgery Partners Inc.
When was the last downgrade for Surgery Partners (SGRY)?
The last downgrade for Surgery Partners Inc happened on June 15, 2022 when B of A Securities changed their price target from N/A to $36 for Surgery Partners Inc.
When is the next analyst rating going to be posted or updated for Surgery Partners (SGRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surgery Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surgery Partners was filed on April 21, 2025 so you should expect the next rating to be made available sometime around April 21, 2026.
Is the Analyst Rating Surgery Partners (SGRY) correct?
While ratings are subjective and will change, the latest Surgery Partners (SGRY) rating was a reiterated with a price target of $35.00 to $35.00. The current price Surgery Partners (SGRY) is trading at is $22.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
